10 September 2009--Synthon is announcing that it has successfully completed multiple decentralized procedures (DCP) for Raloxifene. Regulatory clearance has been obtained for Synthon's product in nearly all European countries. Synthon's Raloxifene 60 mg tablets are a fully generic and bioequivalent version of the brand product Evista®.
The details can be read here.
No comments:
Post a Comment